PPARδ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-17 and is reviewed periodically as new material appears.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
== Gene == The COL2A1 gene is located on the long (q) arm of chromosome 12 between positions 13.11 and 13.2, from base pair 46,653,017 to base pair 46,684,527. The expression of COL2A1 is regulated by SOX-9 and retrotransposon gag-like-3 gene RTL3 in chondrocytes. There are two transcripts identified for this gene.
In July 2020, the studio announced it was working on a new game. The Chinese Room revealed their new game, Still Wakes the Deep, at the Xbox Games Showcase 2023. On 17 July 2023, following the announcement of their new game, co-founder and creative director Dan Pinchbeck announced his departure from the studio after 15 years. At their PAX West panel, Paradox Interactive revealed that the Chinese Room had taken over development duties on Vampire: The Masquerade – Bloodlines 2 from Hardsuit Labs, who were fired from the project in 2021.
Machine learning algorithms require large amounts of data. The techniques used to acquire this data have raised concerns about privacy, surveillance and copyright. AI-powered devices and services, such as virtual assistants and IoT products, continuously collect personal information, raising concerns about intrusive data gathering and unauthorised access by third parties. The loss of privacy is further exacerbated by AI's ability to process and combine vast amounts of data, potentially leading to a surveillance society where individual activities are constantly monitored and analysed without adequate safeguards or transparency. Sensitive user data collected may include online activity records, geolocation data, video, or audio. For example, in order to build speech recognition algorithms, Amazon has recorded millions of private conversations and allowed temporary workers to listen to and transcribe some of them. Opinions about this widespread surveillance range from those who see it as a necessary evil to those for whom it is clearly unethical and a violation of the right to privacy. AI developers argue that this is the only way to deliver valuable applications and have developed several techniques that attempt to preserve privacy while still obtaining the data, such as data aggregation, de-identification and differential privacy. Since 2016, some privacy experts, such as Cynthia Dwork, have begun to view privacy in terms of fairness.
In addition, this allowed Germany to gain control of Czech armament (particularly, the Škoda Works), and get rid of the threat of the Czech army and airfields, which were easily in range of Germany. On 8 March 1939, Hitler met with Wilhelm Keppler, the NSDAP's economic expert, where he spoke about his wish to occupy Czecho-Slovakia for economic reasons, saying that Germany needed its raw materials and industries. Hitler totally ignored the agreements of the Munich Agreement and scheduled a German invasion of Bohemia and Moravia for the morning of 15 March. In the interim, he negotiated with the Slovak People's Party and with Hungary to prepare the dismemberment of the republic before the invasion. On 13 March, he invited Tiso to Berlin and on 14 March, the Slovak Diet convened and unanimously declared Slovak independence. Carpatho-Ukraine also declared independence but Hungarian troops occupied and annexed it on 15 March and a small part of eastern Slovakia as well on 23 March.
Sources: en.wikipedia.org
== Deaths == January 6 – Alex Felipe, 32, futsal player (Sporting CP, Norilsk Nickel, national team) January 10 – Isabel Veloso, 19, social media influencer January 24 – Constantino de Oliveira Júnior, 57, founder and CEO (2004–2012) of Gol Linhas Aéreas February 4 – Ricardo Schnetzer, 72, voice actor February 13 – José Álvaro Moisés, 81, political scientist. April 17 – Oscar Schmidt, 68, Hall of Fame basketball player (JuveCaserta, Corinthians, national team). April 18 – Oscar Andrade, 68, deputy (1996–2003). April 19 – Gerardo Renault, 96, Minas Gerais MLA (1968–1978), deputy (1978–1986). April 27 – Luciana Novaes, 42, social worker, politician, and Rio de Janeiro city councilwoman. May 4 – Hermano da Silva Ramos, 100, French-Brazilian racing driver (Formula One). May 2 – Raimundo Rodrigues Pereira, 85, journalist. May 5 – Guto Graça Mello, 78, composer and music producer. May 23 – Gabriel Ganley, 22, bodybuilder and social media influencer. June 9 – Orlando Senna, 86, film director (Iracema: Uma Transa Amazônica). June 11 – Brito, 86, football player. June 14 – Oliver Tree, 32, American singer-songwriter. Lucas Frota, 27, record producer, musician, and DJ. June 19 – Brasão, 44, footballer (Athletico Paranaense, Santa Cruz, Salgaocar). July 3 – Lydia Möcklinghoff, 45, German ecologist and zoologist. July 7 – Benedito Ruy Barbosa, 95, telenovela writer (Pantanal, O Rei do Gado, Terra Nostra). July 16 – Renato Machado, 83, newscaster and journalist (TV Globo). July 26 – Octavio Gallotti, 95, minister (1984–2000) and president (1991, 1993–1995) of the Supreme Federal Court.
Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company. The drug was developed by Sucampo Pharmaceuticals and approved by the Food and Drug Administration (FDA) in 2006. It was recommended for use in the UK by the National Institute for Health and Care Excellence (NICE) in July 2014. Health Canada approved the drug in 2015. Lubiprostone received approval from the Food and Drug Administration in 2008, to treat irritable bowel syndrome with constipation (IBS-C), and in 2013, for the treatment of opioid-induced constipation in adults with chronic noncancer pain. It is available as a generic medication.
== Chemistry == Peptide analogues of oxytocin with similar actions, for example carbetocin (Duratocin) and demoxytocin (Sandopart), have been developed and marketed for medical use. In addition, small-molecule oxytocin receptor agonists, like TC OT 39, WAY-267464, and LIT-001 have been developed and studied. However, lack of selectivity over vasopressin receptors has so far limited the potential usefulness of small-molecule oxytocin receptor agonists.
immunohistochemistry (IHC) A branch of histochemistry which makes use of antibodies conjugated to some kind of molecular label in order to detect the presence or localization of complementary antigenic structures in tissue samples. See also immunostaining.
ATP is stable in aqueous solutions between pH 6.8 and 7.4 (in the absence of catalysts). At more extreme pH levels, it rapidly hydrolyses to ADP and phosphate. Living cells maintain the ratio of ATP to ADP at a point ten orders of magnitude from equilibrium, with ATP concentrations fivefold higher than the concentration of ADP. In the context of biochemical reactions, the P-O-P bonds are frequently referred to as high-energy bonds.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.